The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Lupus Expert Calls for Better Research, Outcomes of Clinical Trials

Lupus Expert Calls for Better Research, Outcomes of Clinical Trials

July 12, 2016 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF

One approach is to use interferon-alpha to immunize patients so they develop their own antibodies to it. This is now in early- to mid-stage development.

You Might Also Like
  • Mitigate Risk and Increase Success of Lupus Clinical Trials
  • Lupus Treatment Advances Lag Behind Other Rheumatic Diseases
  • Subcutaneous Belimumab Improves Systemic Lupus Srythematosus Outcomes
Explore This Issue
July 2016
Also By This Author
  • EULAR 2015: Anti-Inflammatory Drugs with Dual Targets

Another strategy has been to specifically target interferon-alpha with monoclonal antibodies, of which there are three such products: rontalizumab, which was studied in a failed trial; sifalimumab, which has generated “some excitement” despite response rates of only about 15% with the highest dose studied; and AGS009, which has been through Phase 1.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

A broader effect on the type I interferon pathway occurs with anifrolumab, an antibody that binds to the receptor for all type I interferons. A response rate of 26% above placebo in SLE patients was observed in a Phase 2 trial.

Still another product, in Phase 1 development, is an antibody that reacts with BDCA2, a molecule on plasmacytoid dendritic cells that are the chief producers of interferons.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

B Cells & T Cells

A large Phase 3 trial of an antibody to CD22 ended in a failure, as did trials of two antibodies to CD20, one in SLE and another in LN—although Dr. Furie said “we’re still believers in targeting B cells.”

There are now about 5 trials going on studying rituximab, an anti-CD20 antibody. Plus, Dr. Furie and others are working on an LN trial of obinutuzumab, which is a third-generation anti-CD20 antibody, and seemingly the most potent.

Another highlight has been the revival of hydrochloroquine, which had previously been administered primarily to lupus patients with arthritis or rash, but has been found to have benefits in a lot of different domains, including lowering lipid levels, preventing thrombosis, preventing flares & improving survival.

BLyS Pathway

Still another strategy is to inhibit essential growth factors for B cells through inhibition of the BLyS-APRIL pathway. Belimumab works in this way, and is now FDA approved. But this approach, too, has ended with failed trials, including Phase 3 trials of tabalumab, a Phase 2 trial of blisibimod and Phase 2 trials of atacicept, although development of blisibimod and atacicept continues, Dr. Furie said.

He said the mixed results with the BLyS inhibitors are perplexing.

“Why do certain ones work and other ones fail? I don’t know,” he said. But he added that he suspected that, in some cases, the doses being used may have been too low.

Trials studying drugs that are intended to interfere with the B cell–T cell interaction have ended without success as well.

Cytokines

These are a potential target, but two interleukin (IL) 6 blockers so far—sirukumab and a product known as PF-04236921—have failed. The IL-6 receptor blocker tocilizumab seemed to improve arthritis but was associated with neutropenia.

Better Research Needed

Changes are needed to generate better results, Dr. Furie said. He called for better pre-clinical models and observational studies and short, small early clinical trials that don’t require very many patients.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports, SLE (Lupus) Tagged With: 2016 ACR/ARHP State-of-the-Art Clinical Symposium, American College of Rheumatology, clinical trial, Lupus, outcome, patient care, Research, Rheumatic Disease, SLE, therapy, TreatmentIssue: July 2016

You Might Also Like:
  • Mitigate Risk and Increase Success of Lupus Clinical Trials
  • Lupus Treatment Advances Lag Behind Other Rheumatic Diseases
  • Subcutaneous Belimumab Improves Systemic Lupus Srythematosus Outcomes
  • Oxycodone Capsules Put on Hold; Clinical Trials for Lupus Nephritis & SLE Therapies

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.